Biotech Startups

Luvi develops on-farm fermentation systems that stabilize surplus crops and agricultural sidestreams (such as coffee cherry pulp) into shelf-stable functional ingredients for food and beverage brands. Its first product, Luma, is a fermented Cascara extract rich in polyphenols, natural caffeine, and prebiotic fiber for wellness drinks.

1 investor

Lux Bio develops non-electric, non-toxic lighting products powered by proprietary bioluminescent enzymes, including a water-activated light stick (Lux Light) and a battery-free room-illuminating system (Lux Conduit). Its products are compostable and marketed to commercial, industrial, defense, and consumer users.

1 investor

LyGenesis is a clinical-stage cell therapy company that uses a patient's own lymph nodes as bioreactors to grow functioning ectopic organs. Its allogeneic cell therapies target diseases including end stage liver disease, end stage renal disease, Type 1 diabetes, and aging of the thymus.

1 investor

Lync Bio develops fourth-generation SMART ADC (antibody-drug conjugate) technology for oncology, leveraging proprietary dual-target conjugate design and payload engineering to improve tumor coverage, cellular response, and manufacturability.

1 investor

Lynd Clinical operates a network of clinical research sites in underserved rural and community markets, using technology and local partnerships to expand patient access to clinical trials. The company combines on-the-ground site development with AI-enabled infrastructure to make research populations more representative and accessible to pharmaceutical sponsors.

1 investor

Life sciences company recognized with a 2022 Life Science Innovation Award.

1 investor

Lynx Dx develops MyProstateScore 2.0 (MPS2), a urine test that analyzes 18 gene transcripts to predict the presence of clinically significant prostate cancer. The diagnostic can be run as a biomarker-only test or combined with clinical risk factors, generating individualized patient reports for healthcare providers.

1 investor

Lyra Therapeutics develops biocompatible mesh scaffolds for sustained drug delivery to the sinonasal passages, targeting treatment of chronic rhinosinusitis. The company's proprietary platform uses bioabsorbable polymers and engineered matrices to deliver medication over up to six months with a single administration.

1 investor

Lyrica is a pharmaceutical product used to manage fibromyalgia, a chronic condition characterized by widespread pain and fatigue. The page provides patient education about fibromyalgia symptoms and treatment options including medication, self-care, and exercise.

1 investor

Lysosomal Therapeutics Inc. (LTI) develops small-molecule drug therapies for severe neurological diseases affecting movement and cognition, with a lead candidate, LTI-291, targeting GBA-associated parkinsonism, a form of Parkinson's disease linked to GBA1 gene mutations. The company's drug discovery approach draws on the biological link between common neurodegenerative diseases and rare lysosomal genetic disorders.

1 investor

Lyterian Therapeutics develops pharmaceutical treatments by leveraging protein homeostatic mechanisms to target genetically-validated disease drivers. The company focuses on transformative medicines for patients across multiple disease areas.

1 investor

M20 Genomics develops single-cell and spatial transcriptome sequencing technologies for life science research, drug discovery, and disease diagnosis applications. The company offers proprietary VITA and NATA product lines based on its M20 Seq and M20 Spatial technologies.

1 investor

M3triq offers computational drug design and discovery, generating proteins and molecules such as antibodies, nanobodies, enzymes, binders, and small molecules and ranking candidates through virtual screening, molecular docking, structure prediction, and ADMET triage. It serves biotech and pharmaceutical teams either as a full service campaign run by its scientists or as self-serve AI agents for in-house design and discovery.

1 investor

MaaT Pharma is a clinical-stage biotech developing microbiome-based therapeutics aimed at improving survival in cancer patients through immune modulation. It operates in the oncology and microbiome therapeutics space.

1 investor

A biotech company developing gene therapy treatments for neurodegenerative diseases. The company is led by a founder with extensive clinical and regulatory experience in cell and gene therapy, supported by advisors and board members with deep expertise in neurosurgery, clinical neuroscience, and gene therapy development.

1 investor

MABE Bio, based in São Paulo, develops plant-derived materials and surface finishes. The company applies biotechnology and materials science to create alternatives to conventional inputs for manufacturers and designers.

1 investor

MabGenesis is a Japanese startup biopharmaceutical company that commercializes decades of academic antibody research to develop first-in-class and best-in-class therapeutic monoclonal antibody drugs for both human and animal use. Using its MOURA antibody library and IMPACT high-efficiency monoclonal antibody isolation technology, it targets high-unmet-need areas such as cancer and zoonotic diseases, and has built dog and cat antibody libraries for the veterinary drug market.

1 investor

Macro Biologics develops biotherapeutic products based on amino acid polymer technology for applications in therapeutics and diagnostics. The company serves the biopharmaceutical and medical device sectors.

1 investor

MacroBreed develops improved kelp varieties using genomic technologies to breed seaweed with better growth, resilience, and nutritional properties. The company works in marine biotechnology and sustainable aquaculture.

1 investor

Macrocarbon cultivates seaweed species and processes them into sustainable products for industrial applications across multiple sectors. The company leverages marine science expertise to develop drop-in solutions from macroalgae, particularly Sargassum, to support a transition to a blue bioeconomy.

1 investor

Macromoltek is a computational drug design company that uses a proprietary platform to produce de novo antibody designs, including against difficult targets not accessible through traditional methods. It serves large biopharmaceutical companies and smaller biotechs.

1 investor

Macrotope engineers protein antigens using its patented MacroAntigen/MAV platform, which tunes antigen conformational dynamics to broaden immune response for vaccine and therapeutic antibody discovery. It develops its own vaccine candidates (including for SARS-CoV-2 and related coronaviruses) and offers antibody discovery services to biopharma partners.

1 investor

MAG-LAB provides NMR spectroscopy services combined with selective protein isotope labeling techniques to analyze protein-ligand interactions at atomic resolution for drug discovery. It supports pharmaceutical and medicinal chemistry teams in hit finding, hit-to-lead optimization, binding site mapping, and characterizing challenging targets including intrinsically disordered proteins.

1 investor

Magellan Life Sciences develops X-Seed, a protein engineering platform that uses a precision respiration process to produce complex protein molecules at higher yields with simpler purification. The company applies synthetic biology toward food security, focusing on producing alternatives such as sugar replacements to reduce the environmental impact of traditional farming.

1 investor